FindTrial
Sign In

A retrospective clinical study on osimertinib as a neoadjuvant therapy for resectable stage II-IIIB EGFR-positive non-small cell lung cancer

A retrospective clinical study on osimertinib as a neoadjuvant therapy for resectable stage II-IIIB EGFR-positive non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091032
Enrollment
Unknown
Registered
2024-10-18
Start date
2024-10-20
Completion date
Unknown
Last updated
2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Interventions

Observation group:Osimertinib neoadjuvant therapy

Sponsors

The Second Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with a confirmed EGFR L858R mutation or 19Del before treatment; 2. NSCLC patients who were selected to receive osimertinib as a neoadjuvant therapy; 3. Patients who have undergone surgical treatment; 4. Individuals with clear imaging data (thoracic CT) before and after treatment.

Exclusion criteria

Exclusion criteria: 1. Neoadjuvant therapy combined with any systemic anticancer treatment; 2. Neoadjuvant therapy combined with any local anticancer treatment; 3. Patients with confirmed resistant mutation genes (Kras and T790M).

Design outcomes

Primary

MeasureTime frame
Primary pathological remission rate;—

Secondary

MeasureTime frame
Complete pathological remission rate;Objective preoperative remission rate;R0 resection rate;1-year event free survival rate;Adverse Event, AE;—

Countries

china

Contacts

Public Contactzhou dong

The Second Affiliated Hospital of Army Medical University

449185056@qq.com+86 157 3609 3069

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026